71. Breast cancer risk prediction using Tyrer-Cuzick algorithm with an 18-SNPs polygenic risk score in a European population with below-average breast cancer incidenceTjaša Oblak, Petra Škerl, Benjamin J. Narang, Rok Blagus, Mateja Krajc, Srdjan Novaković, Janez Žgajnar, 2023, original scientific article Abstract: Goals: To determine whether an 18 single nucleotide polymorphisms (SNPs) polygenic risk score (PRS18) improves breast cancer (BC) risk prediction for women at above-average risk of BC, aged 40-49, in a Central European population with BC incidence below EU average. Methods: 502 women aged 40-49 years at the time of BC diagnosis completed a questionnaire on BC risk factors (as per Tyrer-Cuzick algorithm) with data known at age 40 and before BC diagnosis. Blood samples were collected for DNA isolation. 250 DNA samples from healthy women aged 50 served as a control cohort. 18 BC-associated SNPs were genotyped in both groups and PRS18 was calculated. The predictive power of PRS18 to detect BC was evaluated using a ROC curve. 10-year BC risk was calculated using the Tyrer-Cuzick algorithm adapted to the Slovenian incidence rate (S-IBIS): first based on questionnaire-based risk factors and, second, including PRS18. Results: The AUC for PRS18 was 0.613 (95 % CI 0.570-0.657). 83.3 % of women were classified at above-average risk for BC with S-IBIS without PRS18 and 80.7 % when PRS18 was included. Conclusion: BC risk prediction models and SNPs panels should not be automatically used in clinical practice in different populations without prior population-based validation. In our population the addition of an 18SNPs PRS to questionnaire-based risk factors in the Tyrer-Cuzick algorithm in general did not improve BC risk stratification, however, some improvements were observed at higher BC risk scores and could be valuable in distinguishing women at intermediate and high risk of BC. Keywords: early breast cancer, polygenic risk score, risk prediction Published in DiRROS: 21.03.2024; Views: 417; Downloads: 115 Full text (1,54 MB) |
72. |
73. |
74. |
75. Resolving a structural issue in cerium-nickel-based oxide : single compound or a two-phase system?Jelena Kojčinović, Dalibor Tatar, Stjepan Šarić, Cora Pravda Bartus, Andraž Mavrič, Iztok Arčon, Zvonko Jagličić, Maximilian Mellin, Marcus Einert, Angela Altomare, Rocco Caliandro, 2024, original scientific article Keywords: cerium oxide, nickel oxide, crystallography Published in DiRROS: 13.03.2024; Views: 709; Downloads: 599 Full text (4,01 MB) This document has many files! More... |
76. |
77. |
78. Značilnosti in gospodarjenje z gozdovi plemenitih listavcev - habitatni tip Javorovi gozdovi (Natura 2000) : spletni seminar ZGS, Ljubljana, 15. februar 2024Valerija Babij, Lado Kutnar, Janez Kermavnar, Anže Martin Pintar, 2024, other monographs and other completed works Keywords: vegetacija, rastišče, ekologija gozda, gozdovi plemenitih listavcev, gospodarjenje z gozdovi, Natura 2000 Published in DiRROS: 05.03.2024; Views: 483; Downloads: 124 Full text (7,03 MB) |
79. |
80. Preoperative concomitant chemoradiotherapy in esophageal cancerBoštjan Šeruga, Mihael Sok, Janez Eržen, Jože Jerman, Boris Jančar, Branko Zakotnik, 2006, original scientific article Abstract: Background. Currently primary treatment options for esophageal cancer are surgery only or concomitant chemoradiotherapy (CRT) and the long-term survivalof patients with locally advanced disease is rare. Preoperative concomitant CRT seems to be beneficial, mostly in patients who achieve a complete pathologic response (pCR) after CRT. In this retrospective analysis the efficiency and toxicity of preoperative CRT in patients with locally advanced esophageal cancer was analysed as well as the influence of pCR on thesuraival. Patients and metkods From 1996 to 2002 41 patients with locoregionally confined esophageal cancerwere treated with cisplatin 75 mgžm2 and 5-FU 1000 mgžm2 as 4 day contonuous infusion starting on days 1. and 22. with concorrtitant radiotherapy 4500 cGy, 200-300 cGyžday. Esophagectomy followed 4-5 weeks after radiotherapy. After the surgery patients were followed-up regularly at 3-6 months intervals. Results. The pCR was achieved in 26.8% of patients. The overall median survival time was 18 months for all patients, 21.2 months for patients who achieved pCR and 16 months in those with residual disease (p= 0,79). Postoperative mortality rate was 22%. The median dose intensity for cisplatin was 92% and for 5-FU 71.5 of the planned dose. Disease recurred most often locoregionally (31.7%) and the overall recurrence rate was 43.9. Conclusion. Modern radiation techniques and the adequate dose intensity could further improve the locoregional control. The selection of patients without comorbid conditions and without already present distant metastases is essential for this combined treatment approach. Published in DiRROS: 15.02.2024; Views: 432; Downloads: 98 Full text (123,83 KB) |